Donor and transplant characteristics
| Variable . | No. of patients (%) . |
|---|---|
| Donors, related | 547 (54) |
| HLA-matched sibling* | 470 (47) |
| HLA-mismatched/nonsibling† | 77 (8) |
| Unrelated‡ | 460 (46) |
| HLA-matched§ | 266 (26) |
| HLA mismatched‖ | 158 (16) |
| Source of stem cells | |
| Marrow | 502 (50) |
| PBPC¶ | 484 (48) |
| Cord blood | 21 (2) |
| Donor/patient CMV status** | |
| D+/P+ | 280 (28) |
| D+/P− | 112 (11) |
| D−/P− | 272 (27) |
| D−/P+ | 252 (25) |
| Conditioning regimens | |
| BU + CY (± ATG) | 413 (41) |
| FLU + TBI (2–4.5 Gy) | 101 (10) |
| BU + TBI (12 Gy) | 72 (7) |
| FLU + BU | 47 (5) |
| BU + CY + TBI (12 Gy) | 44 (4) |
| 131I-CD45 + FLU + TBI (2 Gy) | 23 (2) |
| FLU + treosulfan | 22 (2) |
| CY + TBI (≥ 12 Gy) ± ATG | 216 (21) |
| Other | 69 (7) |
| GVHD prophylaxis†† | |
| CSP + MTX | 659 (65) |
| Tacrolimus + MTX | 136 (14) |
| MMF + CSP/tacrolimus | 101 (10) |
| CSP ± steroids | 58 (6) |
| Other | 44 (4) |
| None‡‡ | 9 (1) |
| Variable . | No. of patients (%) . |
|---|---|
| Donors, related | 547 (54) |
| HLA-matched sibling* | 470 (47) |
| HLA-mismatched/nonsibling† | 77 (8) |
| Unrelated‡ | 460 (46) |
| HLA-matched§ | 266 (26) |
| HLA mismatched‖ | 158 (16) |
| Source of stem cells | |
| Marrow | 502 (50) |
| PBPC¶ | 484 (48) |
| Cord blood | 21 (2) |
| Donor/patient CMV status** | |
| D+/P+ | 280 (28) |
| D+/P− | 112 (11) |
| D−/P− | 272 (27) |
| D−/P+ | 252 (25) |
| Conditioning regimens | |
| BU + CY (± ATG) | 413 (41) |
| FLU + TBI (2–4.5 Gy) | 101 (10) |
| BU + TBI (12 Gy) | 72 (7) |
| FLU + BU | 47 (5) |
| BU + CY + TBI (12 Gy) | 44 (4) |
| 131I-CD45 + FLU + TBI (2 Gy) | 23 (2) |
| FLU + treosulfan | 22 (2) |
| CY + TBI (≥ 12 Gy) ± ATG | 216 (21) |
| Other | 69 (7) |
| GVHD prophylaxis†† | |
| CSP + MTX | 659 (65) |
| Tacrolimus + MTX | 136 (14) |
| MMF + CSP/tacrolimus | 101 (10) |
| CSP ± steroids | 58 (6) |
| Other | 44 (4) |
| None‡‡ | 9 (1) |
ATG indicates antithymocyte globulin; CSP, cyclosporine; MTX, methotrexate; and MMF, mycophenolate mofetil.
Including 9 syngeneic twins.
HLA mismatches typically involved one class I or class II antigen.
In 36 patients, high-resolution typing was not available.
HLA-matched at the allele level by high-resolution typing.
HLA-mismatched for one antigen, 1 or 2 alleles, or 1 antigen plus 1 allele.
Including 4 patients who receive PBPC + marrow.
Information incomplete in 91 cases.
In addition, 15 patients received ATG and 28 sirolimus in combination with various regimens.
Patients were transplanted from syngeneic twin donors.